company background image
ARGX logo

argenx NasdaqGS:ARGX Stock Report

Last Price

US$604.96

Market Cap

US$36.4b

7D

1.8%

1Y

62.9%

Updated

14 Mar, 2025

Data

Company Financials +

ARGX Stock Overview

A biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More details

ARGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price€604.96
52 Week High€678.21
52 Week Low€349.86
Beta0.20
1 Month Change-6.80%
3 Month Change-0.37%
1 Year Change62.94%
3 Year Change95.21%
5 Year Change409.05%
Change since IPO2,530.26%

Recent News & Updates

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Recent updates

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

Feb 27

argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)

Jan 23

Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat

Oct 31

argenx: Myositis Data Could Add Billions In Value

Sep 25

Argenx: Strong Setup For Outperformance In 2025

Jun 28

argenx: Innovation Over Losses In Autoimmune Arena

May 07

argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion

Feb 01

Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod

Sep 21

Argenx's neuromuscular disorder drug Vyvgart wins approval in EU

Aug 11

Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M

Jul 28

argenx: A Very Good Start For Vyvgart

May 25

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

May 18

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

Mar 07

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

Dec 22

argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Nov 30

argenx: R&D Day Goes Unnoticed

Aug 23

argenx: Next Phase Of Growth With Efgartigimod And ARGX-117

Jun 30

Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals

Jun 07

Argenx raises ~$1B in global offering

Feb 03

argenx to raise $750M in proposed global offering

Feb 01

Shareholder Returns

ARGXUS BiotechsUS Market
7D1.8%-1.2%-4.1%
1Y62.9%-5.6%6.6%

Return vs Industry: ARGX exceeded the US Biotechs industry which returned -5.6% over the past year.

Return vs Market: ARGX exceeded the US Market which returned 6.6% over the past year.

Price Volatility

Is ARGX's price volatile compared to industry and market?
ARGX volatility
ARGX Average Weekly Movement3.7%
Biotechs Industry Average Movement10.8%
Market Average Movement6.4%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.4%

Stable Share Price: ARGX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ARGX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,148Tim Van Hauwermeirenwww.argenx.com

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
ARGX fundamental statistics
Market capUS$36.39b
Earnings (TTM)US$833.04m
Revenue (TTM)US$2.25b

43.7x

P/E Ratio

16.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARGX income statement (TTM)
RevenueUS$2.25b
Cost of RevenueUS$1.21b
Gross ProfitUS$1.04b
Other ExpensesUS$208.29m
EarningsUS$833.04m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)13.71
Gross Margin46.24%
Net Profit Margin36.99%
Debt/Equity Ratio0%

How did ARGX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 22:08
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

argenx SE is covered by 49 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles Pitman-KingBarclays
Richard ParkesBNP Paribas Exane